Vitamin D3 (Low dose) — Competitive Intelligence Brief

Vitamin D3 (Low dose) (Vitamin D3 (Low dose)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Vitamin D analog. Area: Endocrinology, Nephrology, Rheumatology.

phase 3 Vitamin D analog Endocrinology, Nephrology, Rheumatology Small molecule

Target snapshot

Vitamin D3 (Low dose) (Vitamin D3 (Low dose)) — Shiraz University of Medical Sciences. Vitamin D3 is a fat-soluble vitamin that plays a crucial role in maintaining strong bones, immune function, and overall health.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Vitamin D3 (Low dose) TARGET	Vitamin D3 (Low dose)	Shiraz University of Medical Sciences	phase 3	Vitamin D analog
Dovonex	CALCIPOTRIENE		marketed	Vitamin D Analog [EPC]	Vitamin D3 receptor	1993-01-01
calcipotriene + clobetasol propionate	calcipotriene + clobetasol propionate	Leon Kircik, M.D.	marketed	Topical combination therapy (vitamin D analog + corticosteroid)	Vitamin D receptor (VDR) and glucocorticoid receptor (GR)
Enstilar® foam	Enstilar® foam	Icahn School of Medicine at Mount Sinai	marketed	Topical corticosteroid + vitamin D analog combination	Glucocorticoid receptor; vitamin D receptor (VDR)
Taclonex Topical Suspension	Taclonex Topical Suspension	University of Pittsburgh	marketed	Combination topical agent (vitamin D analog + corticosteroid)	Vitamin D receptor (VDR) and glucocorticoid receptor (GR)
Calcipotriene/betamethasone	Calcipotriene/betamethasone	Derm Research, PLLC	marketed	Vitamin D analog / Corticosteroid combination	Vitamin D receptor (VDR) / Glucocorticoid receptor (GR)
Calcipotriene and betamethasone dipropionate ointment	Calcipotriene and betamethasone dipropionate ointment	Galderma R&D	marketed	Topical combination therapy (vitamin D analog + corticosteroid)	Vitamin D receptor (VDR) and glucocorticoid receptor (GR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

• 2028-05-07 — Dovonex · 8263580 · Formulation · US

Sponsor landscape (Vitamin D analog class)

1. LEO Pharma · 2 drugs in this class
2. Genzyme, a Sanofi Company · 2 drugs in this class
3. National Cancer Institute, Naples · 2 drugs in this class
4. OPKO Health, Inc. · 2 drugs in this class
5. Joslin Diabetes Center · 1 drug in this class
6. Kyowa Kirin, Inc. · 1 drug in this class
7. Maimónides Biomedical Research Institute of Córdoba · 1 drug in this class
8. Shanghai Jiao Tong University Affiliated Sixth People's Hospital · 1 drug in this class
9. Shiraz University of Medical Sciences · 1 drug in this class
10. St. Justine's Hospital · 1 drug in this class